Overview
Acute myeloid leukemia (AML) is an aggressive blood cancer that often requires intensive treatment followed by allogeneic hematopoietic stem cell transplantation (allo-SCT), also called an allogeneic stem cell transplant. Even when patients appear to be in remission before transplant, tiny numbers of leukemia cells can remain in the body. These cells are known as measurable residual disease (MRD), and they can strongly influence the risk of relapse and survival after transplantation.
A new study published in Haematologica evaluated a cost-conscious next-generation sequencing (NGS) approach for MRD detection in AML. The results suggest that this method can identify patients at higher risk of poor outcomes before transplant, potentially helping doctors personalize treatment more effectively.
